Community-level physiological profiling (CLPP) based on sole carbon substrate utilization profiles (CSUP) is a rapid screening method used to characterize microbial communities of different habitats, ranging between sediments to seawater and between oligotrophic groundwater to soil and fertilizers.

Biolog’s carbon source utilization technology identifies environmental and pathogenic microorganisms by producing a characteristic pattern or “metabolic fingerprint” from discrete test reactions performed within a 96 well microplate. …

Biolog phenotype assays achieve this by coupling tetrazolium dyes with minimally defined nutrients to measure the impact of hundreds of carbon, nitrogen, phosphorous, and sulfur sources on redox reactions that result from compound-induced effects on the electron transport chain.

An EcoPlate is a 96-well microplate that contains 31 common carbon sources from altogether five compound groups—that is, carbohydrates, carboxylic and ketonic acids, amines and amides, amino acids and polymers—plus a blank well as a control, all these replicated thrice to control variation in inoculum densities.

Each EcoPlate is filled with a dilution of one soil suspension, thus representing one soil sample. The utilization rates of carbon compounds in the wells are quantified spectrophotometrically by following the reduction of water-soluble colourless triphenyl tetrazolium chloride to purple triphenyl formazan.

A. INTRODUCTION TO THE CONTROL OF MICROORGANISMS Physical agents include such methods of control as high or low temperature, desiccation, osmotic pressure, radiation, and filtration. Control by chemical agents refers to the use of disinfectants, antiseptics, antibiotics, and chemotherapeutic antimicrobial chemicals.

Array BioPharma also entered into clinical research collaborations with Merck and Bristol-Myers Squibb to study binimetinib plus anti-PD-1 therapy in patients with microsatellite stable metastatic CRC (or “MSS CRC”). The trial with Merck will investigate the safety and efficacy of binimetinib with Merck’s KEYTRUDA ® (pembrolizumab).

BOULDER, Colo. , March 5, 2019 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer , will speak at the 39 th Annual Cowen Health Care Conference in Boston . The public is welcome to participate in the conference through a webcast on the

Array’s European partner, Pierre Fabre, remains on track to file the Marketing Authorization Applications for binimetininb and encorafenib during the summer 2017.

Phenotype MicroArrays are preconfigured sets of phenotypic tests deployed on microplate panels. Each well of the array is designed to test a different phenotype after inoculation with a standardized cell suspension, allowing simultaneous testing of thousands of phenotypes in a single experiment.